You’ve probably heard about the dramatic weight loss that can happen when you take Ozempic or Wegovy. These medications mimic ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

Starting next year, insurance companies, including Highmark, will introduce stricter requirements for covering GLP-1 weight ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...

Experts from the American Heart Association have released a stroke-prevention guide featuring 'Life's Essential 8' amid a ...

The S&P/TSX Composite is having a strong year, up 23 per cent so far, but the economy stinks to the point that one economist ...

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy ...